Annual report pursuant to Section 13 and 15(d)

Segment Reporting - Schedule of Information about Reported Segment Profit or Loss and Assets (Details)

v3.21.1
Segment Reporting - Schedule of Information about Reported Segment Profit or Loss and Assets (Details) - USD ($)
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues $ 5,207,000
Operating loss (14,081,000)  
Financing expenses, net (14,312,000) (5,333,000)
Share in losses of affiliated companies accounted for under equity method, net (1,200,000) (2,966,000)
Net loss (29,773,000) (11,815,000)
Total assets 6,009,000 $ 91,000
Total expenditures for assets of reportable segments 2,030,000  
Total depreciation for reportable segments (96,000)  
Breast Cancer Test [Member]    
Revenues  
Operating loss (4,943,000)  
Net loss (4,943,000)  
Total assets 1,554,000  
Total expenditures for assets of reportable segments 24,000  
Total depreciation for reportable segments (28,000)  
Alzheimer [Member]    
Revenues  
Operating loss (8,327,000)  
Net loss (8,327,000)  
Total assets  
Total expenditures for assets of reportable segments  
Total depreciation for reportable segments  
COVID-19 Testing [Member]    
Revenues 5,207,000  
Operating loss (991,000)  
Net loss (991,000)  
Total assets 4,455,000  
Total expenditures for assets of reportable segments 2,006,000  
Total depreciation for reportable segments $ (68,000)